Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Anne C. Deitz"'
Autor:
Torben Steiniche, Jeanette Baehr Georgsen, Peter Meldgaard, Anne C. Deitz, Mark Ayers, M. Catherine Pietanza, Ke Zu
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
ObjectivesPrevalence of tumor PD-L1 expression in extensive-stage small-cell lung cancer (ES-SCLC) is variable, and data on PD-L2 expression are limited. The prognostic values of these biomarkers are not well understood. The current study was conduct
Externí odkaz:
https://doaj.org/article/0e341a629a114946a42908cbc65c32ea
Autor:
Yuting Kuang, Rajpal Singh, Arianna Nevo, Anne C. Deitz, M. Catherine Pietanza, Aixue Liu, Jennifer Uyei, Ke Zu
Publikováno v:
Clinical Lung Cancer. 23:659-669
Severe pneumonitis (≥ grade 3 by Common Terminology Criteria for Adverse Events [CTCAE]) is a toxicity associated with concurrent chemoradiation therapy (CCRT), which is the standard first-line treatment for patients with limited-stage small cell l
Autor:
Yuting Kuang, Christine M. Pierce, Hsiu-Ching Chang, Alexandra Z. Sosinsky, Anne C. Deitz, Steven M. Keller, Ayman Samkari, Jennifer Uyei
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 174
High-grade pneumonitis is a severe and potentially life-threatening adverse event associated with concurrent chemoradiation (cCRT) in patients with non-small cell lung cancer (NSCLC). The aim of this study was to summarize and quantify the incidence
Autor:
Upal Basu Roy, Wendy Selig, Andrea Ferris, Yutao Gong, Meredith K. Chuk, Gideon M. Blumenthal, Nina Stuccio, P. Bonomi, Anne C. Deitz, Alexander Spira, C. J. Delgra, Jinghua He
Publikováno v:
Therapeutic Innovation & Regulatory Science. 54:1208-1214
Expedited reporting of unexpected serious adverse reactions that occur during clinical trials conducted under an IND is a critical component of the clinical trial process designed to protect patients by identifying potential safety issues with new ag
Autor:
Lu Si, Jun Ge, Xuan Wang, Chi Zhihong, Anne C. Deitz, Ben Li, Chuanliang Cui, Li Zhou, Xue Bai, Bin Lian, Haiyan Wu, Siming Li, Sheng Xinan, Lili Mao, Jun Guo, Xieqiao Yan, Shusen Liu, Jianfeng Li, Bixia Tang
Publikováno v:
International Journal of Surgery Oncology. 4:e761-e767
Introduction: Treatment options for advanced melanoma in China are lacking, particularly second-line therapies. The aim of this retrospective observational study was to describe the real-world effectiveness of available anticancer therapies in patien
Publikováno v:
Neuro Oncol
BACKGROUND NF1-related PN can cause substantial morbidity, with no currently approved drug treatment available for PN treatment. Although surgery is the standard of care, complete resection of PN is often difficult due to encasement of vital structur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1383ee5bfbd50fb88ff033ea4114329
https://europepmc.org/articles/PMC6847350/
https://europepmc.org/articles/PMC6847350/
Autor:
Martin Reck, Rina Hui, Maya Gottfried, Gregory M. Lubiniecki, Sinead Cuffe, Suman Rao, Katsuyuki Hotta, Tibor Csőszi, Anne C. Deitz, Delvys Rodriguez-Abreu, Julie R. Brahmer, Nir Peled, Mary O'Brien, Andrew G. Robinson, Ali Tafreshi, Andrea Fülöp, Jin Zhang, Reshma A. Rangwala
Publikováno v:
The Lancet Oncology. 18:1600-1609
Summary Background In the phase 3 KEYNOTE-024 trial, treatment with pembrolizumab conferred longer progression-free survival than did platinum-based therapy in patients with treatment-naive, advanced non-small-cell lung cancer (NSCLC) with a programm
Autor:
Maria Catherine Pietanza, Ke (Kirsten) Zu, Anne C. Deitz, Jennifer Uyei, Mike Liu, Arianna Nevo, Yuting Kuang, Darpan Darpan
Publikováno v:
Journal of Clinical Oncology. 39:e20592-e20592
e20592 Background: Concurrent chemoradiation (cCRT) has been the standard first line treatment for patients with limited-stage small cell lung cancer (LS-SCLC) for decades. Despite continued progress in refining chemotherapy and radiation modalities,
Autor:
Yuting Kuang, Christine M. Pierce, Anne C. Deitz, Steven M. Keller, Jennifer Uyei, Bilal Piperdi, Arianna Nevo, Hsiu-Ching Chang
Publikováno v:
Journal of Clinical Oncology. 39:e20532-e20532
e20532 Background: Recent clinical trials have shown positive results for therapies combining concurrent chemoradiation therapy (cCRT) and checkpoint immunotherapy in unresectable non-small cell lung cancer (NSCLC). cCRT is associated with an increas
Autor:
Anne C. Deitz, Ke (Kirsten) Zu, Mark Ayers, Jeanette Bæhr Georgsen, Maria Catherine Pietanza, Peter Meldgaard, Torben Steiniche
Publikováno v:
Zu, K K, Georgsen, J B, Meldgaard, P, Deitz, A, Ayers, M, Pietanza, M C & Steiniche, T 2021, ' Protein expression of programmed cell death ligand 1 and ligand 2 and their prognostic values in extensive-stage small cell lung cancer. ', Journal of Clinical Oncology, vol. 39, no. 15 suppl, pp. e20593-e20593 . https://doi.org/10.1200/JCO.2021.39.15_suppl.e20593
e20593 Background: The receptor-ligand interaction between programmed cell death protein-1 (PD-1) and its ligands (PD-L1 and PD-L2) plays a critical role in tumor immune evasion and has become a therapeutic target in a number of cancer types, includi